Related Experiment Video
Updated: Jul 4, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Stage T2 prostate cancer presented with high serum prostate specific antigen and nonspecific bone lesions
T Pejcic1, J Hadzi-Djokic, B Markovic
1Clinical Center of Serbia, Institute for Urology and Nephrology, Belgrade.
Objective:
To present the case of T2 prostate cancer (PCa) mimicking disseminated PCa that was successfully treated with radical retropubic prostatectomy (RRP). PATIENT AND THE METHOD: The patient had prostate specific antigen (PSA) level higher than 30 ng/ml and multiple atypical lesions on bone scan. TRUS-guided biopsy proved small PCa, only in 1/18 biopsy cores, with Gleason grade 6 (3+3). Bone lesions appeared to be posttraumatic.
Result:
The patient underwent RRP; six months after surgery there is no evidence of the disease.
Conclusion:
Serum PSA level is the sum of cancer activity, normal and BHP tissue production, as well as the result of other pathological conditions, like prostatitis. In some cases, inflammation can be responsible for high PSA level and over-staging.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
06:32Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
Published on: November 4, 2022
